Hematological malignancies are known to have a multitude of aberrations across the genome, including somatic mutations, fusion genes, and copy number alterations. Yet no one technology can efficiently assess all of these aberration types, making the profiling of hematological malignancies time- and labor-intensive.
The genetic complexity of cancer cells in hematological malignancies requires a comprehensive approach for detection of relevant changes. The identification of copy number gains and losses, LOH, cnLOH, clonal heterogeneity, and ploidy status as well as mosaicism are all critical for evaluating blood cancer samples to discover new biomarkers.
You’re invited to QIAGEN Digital Insights’ annual Break the Data Bottleneck Summit, a free-to-attend, two-part virtual event exploring how diagnostic labs can lower the barrier to adopt large cancer genomic profiling.
A two-part event, the Break the Data Bottleneck Summit will explore how small to mid-sized clinical diagnostic labs can compete to offer comprehensive genomic profiling services for precision oncology with the same speed and confidence of hospital networks and university centers.
Clinical decision support software integrated with professional services for evidence-based reporting of NGS oncology tests at scale
Professional variant interpretation service for oncology NGS tesitng
Learn more about QIAGEN’s QIAseq Multimodal Panels for comprehensive genomic profiling of solid tumors and hematological malignancies.